ATE247949T1 - Arzneistoffverabreichungssystem mit zweistufigem targeting - Google Patents
Arzneistoffverabreichungssystem mit zweistufigem targetingInfo
- Publication number
- ATE247949T1 ATE247949T1 AT98962780T AT98962780T ATE247949T1 AT E247949 T1 ATE247949 T1 AT E247949T1 AT 98962780 T AT98962780 T AT 98962780T AT 98962780 T AT98962780 T AT 98962780T AT E247949 T1 ATE247949 T1 AT E247949T1
- Authority
- AT
- Austria
- Prior art keywords
- drug
- delivery system
- drug delivery
- target
- cells
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title abstract 4
- 230000008685 targeting Effects 0.000 title abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 238000004458 analytical method Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
- A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704549A SE513149C2 (sv) | 1997-12-05 | 1997-12-05 | Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna |
| PCT/SE1998/002231 WO1999029302A1 (en) | 1997-12-05 | 1998-12-04 | Drug delivery system with two-step targeting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE247949T1 true ATE247949T1 (de) | 2003-09-15 |
Family
ID=20409286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98962780T ATE247949T1 (de) | 1997-12-05 | 1998-12-04 | Arzneistoffverabreichungssystem mit zweistufigem targeting |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6562316B1 (de) |
| EP (1) | EP1033972B1 (de) |
| JP (1) | JP2001525356A (de) |
| AT (1) | ATE247949T1 (de) |
| AU (1) | AU745059B2 (de) |
| CA (1) | CA2312767C (de) |
| DE (1) | DE69817602T2 (de) |
| DK (1) | DK1033972T3 (de) |
| SE (1) | SE513149C2 (de) |
| WO (1) | WO1999029302A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739313A (en) | 1995-11-13 | 1998-04-14 | Regents Of The University Of Minnesota | Radionuclide labeling of vitamin B12 and coenzymes thereof |
| EP0963758A3 (de) * | 1998-05-07 | 2000-03-22 | Universiteit Gent | Synthetische polyamiosaure Komplexen zur Verabreichung von Nukleinsäuren zur Zielzellen |
| DE19905094C1 (de) * | 1999-02-01 | 2000-10-12 | Schering Ag | Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel |
| US6806363B1 (en) | 1999-04-16 | 2004-10-19 | Mayo Foundation For Medical Education & Research | Cobalamin conjugates useful as antitumor agents |
| KR100642955B1 (ko) | 1999-04-23 | 2006-11-10 | 알자 코포레이션 | 방출성 결합 및 그를 함유하는 조성물 |
| US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
| US7303760B2 (en) | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
| US7591995B2 (en) | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
| US20060177416A1 (en) | 2003-10-14 | 2006-08-10 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
| TWI228512B (en) | 2000-10-25 | 2005-03-01 | Mayo Foundation | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| WO2006108052A2 (en) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| JP5192384B2 (ja) | 2005-09-22 | 2013-05-08 | メディバス エルエルシー | ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法 |
| PL2889043T3 (pl) | 2008-12-16 | 2019-09-30 | Genzyme Corporation | Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko |
| US8808733B2 (en) | 2009-03-31 | 2014-08-19 | The Board Of Trustees Of The University Of Arkansas | Method of controlled drug release from a liposome carrier |
| WO2012112317A1 (en) * | 2011-02-15 | 2012-08-23 | Albert Einstein College Of Medicine Of Yeshiva University | Radiobacteria for therapy of cancer |
| EP2723801B1 (de) | 2011-06-23 | 2017-01-18 | DSM IP Assets B.V. | Neue biologisch abbaubare polyesteramid-copolymere zur arzneimittelabgabe |
| US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
| US9849087B2 (en) | 2011-11-08 | 2017-12-26 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for X-ray induced release from pH sensitive liposomes |
| CN107106509B (zh) | 2014-12-18 | 2021-11-30 | 帝斯曼知识产权资产管理有限公司 | 用于递送酸敏感药物的药物递送系统 |
| EP3368687B1 (de) * | 2015-10-27 | 2021-09-29 | The Broad Institute, Inc. | Zusammensetzungen und verfahren gegen krebsspezifische sequenzvariationen |
| US12336779B2 (en) | 2019-08-01 | 2025-06-24 | Indian Institute Of Science | Method for locomotion of a nanorobot and implementations thereof |
| CA3160955A1 (en) | 2019-11-12 | 2021-05-20 | Dsm Ip Assets B.V. | Polyesteramide copolymers possessing high glass transition temperatures |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2613937B1 (fr) * | 1987-04-17 | 1989-07-21 | Ire Celltarg Sa | Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer |
| US5328678A (en) * | 1987-11-04 | 1994-07-12 | Vestar, Inc. | Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy |
| US5620689A (en) * | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
| IE914220A1 (en) * | 1990-12-10 | 1992-06-17 | Akzo Nv | Labelled, modified oligonucleotides |
| DE69230622T2 (de) * | 1991-10-31 | 2000-07-20 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Bistriazene als chemotherapeutische wirkstoffe |
| US5750390A (en) * | 1992-08-26 | 1998-05-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene |
| US5674977A (en) * | 1993-02-05 | 1997-10-07 | The Ontario Cancer Institute | Branched synthetic peptide conjugate |
| US5648532A (en) * | 1993-06-03 | 1997-07-15 | The Regents Of The University Of California | Compositions for boron neutron capture therapy and methods thereof |
| AU701451B2 (en) * | 1993-10-15 | 1999-01-28 | Eva M. Rakowicz-Szulczynska | Detection and treatment of breast and gynecological cancer |
| US6180766B1 (en) * | 1993-12-02 | 2001-01-30 | Raymond F. Schinazi | Nucleosides and oligonucleotides containing boron clusters |
| US5599796A (en) * | 1993-12-02 | 1997-02-04 | Emory University | Treatment of urogenital cancer with boron neutron capture therapy |
| CA2185671A1 (en) * | 1994-03-15 | 1995-09-21 | Prizm Pharmaceuticals, Inc. | Heparin-binding growth factors for gene therapy and anterior eye disorders |
| US5630786A (en) * | 1994-06-27 | 1997-05-20 | Ionix Corporation | Boron neutron capture enhancement of fast neutron therapy |
| US5756668A (en) * | 1994-11-15 | 1998-05-26 | The Johns Hopkins University School Of Medicine | Hypermethylated in cancer polypeptide, HIC-1 |
| US5643599A (en) * | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| AU710170B2 (en) * | 1996-05-08 | 1999-09-16 | Nika Health Products Limited | Cationic virosomes as transfer system for genetic material |
| AU2911197A (en) * | 1996-05-24 | 1998-01-05 | Imperial College Of Science, Technology And Medicine | Polycationic sterol derivatives as transfection agents |
-
1997
- 1997-12-05 SE SE9704549A patent/SE513149C2/sv not_active IP Right Cessation
-
1998
- 1998-12-04 DK DK98962780T patent/DK1033972T3/da active
- 1998-12-04 AU AU17938/99A patent/AU745059B2/en not_active Ceased
- 1998-12-04 US US09/555,329 patent/US6562316B1/en not_active Expired - Fee Related
- 1998-12-04 AT AT98962780T patent/ATE247949T1/de not_active IP Right Cessation
- 1998-12-04 EP EP98962780A patent/EP1033972B1/de not_active Expired - Lifetime
- 1998-12-04 JP JP2000523974A patent/JP2001525356A/ja active Pending
- 1998-12-04 WO PCT/SE1998/002231 patent/WO1999029302A1/en not_active Ceased
- 1998-12-04 DE DE69817602T patent/DE69817602T2/de not_active Expired - Lifetime
- 1998-12-04 CA CA002312767A patent/CA2312767C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2312767C (en) | 2009-04-07 |
| AU1793899A (en) | 1999-06-28 |
| WO1999029302A1 (en) | 1999-06-17 |
| EP1033972A1 (de) | 2000-09-13 |
| SE9704549L (sv) | 1999-06-06 |
| DK1033972T3 (da) | 2003-12-22 |
| JP2001525356A (ja) | 2001-12-11 |
| AU745059B2 (en) | 2002-03-07 |
| SE9704549D0 (sv) | 1997-12-05 |
| CA2312767A1 (en) | 1999-06-17 |
| SE513149C2 (sv) | 2000-07-17 |
| DE69817602D1 (de) | 2003-10-02 |
| DE69817602T2 (de) | 2004-06-24 |
| US6562316B1 (en) | 2003-05-13 |
| EP1033972B1 (de) | 2003-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69817602D1 (de) | Arzneistoffverabreichungssystem mit zweistufigem targeting | |
| NZ336511A (en) | Treating prostatic diseases using delayed and/or sustained release formulations of activated vitamin D | |
| MY116474A (en) | Potentiation of temozolomide in human tumour cells | |
| EP1455840A4 (de) | Behandlung von krebs bei menschen mit adenovirus-vektor tnf-alpha | |
| Neuwelt et al. | In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity | |
| AU3354500A (en) | Dramatic simplification of a method to treat neoplastic disease by radiation | |
| AU4338501A (en) | Combination chemotherapy | |
| WO2021174195A8 (en) | Use of thyromimetics for the treatment of cancer | |
| AU2001236529A1 (en) | Combination therapy for cancer | |
| WO2005013802A3 (en) | Trefoil factor 3 (tff3) as a target for anti-cancer therapy | |
| Dische | Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma | |
| RU94035764A (ru) | Способ лечения онкологического заболевания | |
| Clark et al. | Biologic treatment of human cancer | |
| AU6955396A (en) | Combination therapy for advanced cancer comprising temozolomide and cisplatin | |
| Hopkins et al. | The effect of varying the time between irradiation and cyclophosphamide on growth response of hepatoma 3924A | |
| Hopkins et al. | Synchronization of host and tumor responses for sequential therapy in experimental solid tumors | |
| DE69724228D1 (de) | Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten | |
| UA30257A (uk) | Спосіб нормалізації тканинного обміну та відновлення морфофункціонального стану органів і тканин | |
| RU94021014A (ru) | Способ лечения злокачественных опухолей методом фотодинамической терапии | |
| Dörr | 100The three A's of normal tissue repopulation: cceleration, symmetry loss, and bortive divisions | |
| IL153586A0 (en) | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer | |
| Meral et al. | Role of vitamin E in decreasing the toxic effect of digoxin | |
| Struwig | Microcurrent therapy | |
| UA20727A (uk) | Спосіб лікуваhhя раку легеhі шляхом хіміоімуhотерапії | |
| Thames | 102Altered fractionation: The past and the future |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |